Johnson & Johnson

NYSE:JNJ  
168.50
+0.76 (+0.45%)
Earnings Announcements

Sema4 Says Entered Into Research Agreement With Janssen Research & Development Llc To Optimize Oncology Clinical Trials

Published: 09/29/2020 12:36 GMT
Johnson & Johnson (JNJ) - Sema4 - Entered Into Research Agreement With Janssen Research & Development, Llc to Optimize Oncology Clinical Trials.
Sema4 - Will Provide Janssen Access to Co's Industry-leading Genomic Testing and Its Proprietary Centrellis Health Intelligence Platform.
Revenue is expected to be $22.52 Billion
Adjusted EPS is expected to be $2.29

Next Quarter Revenue Guidance is expected to be $23.45 Billion
Next Quarter EPS Guidance is expected to be $2.40

More details on our Analysts Page.